Non-Melanoma Skin Cancer Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025- Increasing prevalence of skin cancer globally is anticipated to drive the growth of Global Non-Melanoma Skin Cancer Market.
Global Non-Melanoma Skin Cancer Market is expected to reach more than USD 659.7 Million by 2025 with a CAGR of 6.2% over the forecast period.
Non-melanoma skin cancer (NMSC) is by far the most frequently diagnosed cancer around the globe. It is also one of the most common occupational diseases in Europe and its prevalence continues to increase. It affects more men than women and is more common in the elderly. It refers to the all types of cancer that occur in the skin which are not melanoma. Sometimes cells in the skin, change and no longer grow normally. These changes may lead to non-cancerous growths such as moles, dermatofibromas, warts and skin tags. But in some cases, these changes can cause non-melanoma skin cancer. It starts in round cells called basal cells and this type of cancer is called basal cell carcinoma (BCC) and makes up about 75%–80% of all skin cancers. It can also start in squamous cells of the skin and this type of cancer is called squamous cell carcinoma (SCC) and makes up about 20% of all skin cancers. Non-melanoma skin cancer treatment depends on the type, size and location of cancer. Surgery is the main treatment for non-melanoma skin cancer which involves the removal of cancerous tumour and some of the surrounding skin. Other treatments include; freezing (cryotherapy), anti-cancer creams, radiotherapy and a form of light treatment called photodynamic therapy (PDT).
Get Sample Copy of This Premium Report @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72780&RequestType=Sample
Global Non-Melanoma Skin Cancer Market report is segmented on the basis of drug type, application, end-user and region & country level. Based upon drug type, global non-melanoma skin cancer market is classified into radiation therapy, photodynamic therapy and chemotherapy. Radiation therapy is further sub-divided into electronic brachytherapy, external beam radiation therapy and superficial radiation therapy. Based upon application, global non-melanoma skin cancer market is divided into basal cell carcinoma, T-cell lymphoma, squamous cell carcinoma and others. Based on end-user, the non-melanoma skin cancer market is classified into hospitals, specialty clinics and ambulatory surgical centers.
The regions covered in this Global Non-Melanoma Skin Cancer Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of non-melanoma skin cancer is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Key Players for Global Non-Melanoma Skin Cancer Market Report–
Some major key players for Global Non-Melanoma Skin Cancer Market are Almirall S.A., Novartis AG, Mylan NV, Boehringer Ingelheim GmbH, Sensus Healthcare, iCAD, Inc., Accuray, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, Elekta AB, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Varian Medical Systems, Inc., Ion Beam Applications SA and others.
News-
Nicotinamide for Photoprotection and Skin Cancer Chemoprevention: A Review of Efficacy and Safety.
January 30th, 2019; According to a recent review article published in the journal Experimental Dermatology; Nicotinamide offers various photoprotective and anti-inflammatory effects, and phase III evidence now supports its ability to reduce non-melanoma skin cancers and actinic keratoses in high-risk patients. Researchers examined the role of nicotinamide, a water-soluble vitamin B3 derivative that reduces ATP levels and inhibits glycolysis, thereby preventing an energy crisis. They found that randomized controlled clinical trials have demonstrated that nicotinamide limits transepidermal water loss and the growth of non-melanoma skin cancer in high-risk individuals. In addition, they found that patients with normal renal function tolerate nicotinamide well with minimal, if any, side effects, even at doses of about 1 g daily. However, diarrhea was reported among patients on hemodialysis—especially those taking phosphate binders.
Request for Methodology @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72780&RequestType=Methodology
Increasing Prevalence of Skin Cancer Globally, Drives the Growth of Global Non-Melanoma Skin Cancer Market
The major factors driving the growth of global non-melanoma skin cancer market are increasing prevalence of skin cancer and growing awareness regarding its treatment. For example; As per WHO; Currently, between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. According to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime. And as per World Cancer Research Fund International; Non-melanoma skin cancer is the 5th most commonly occurring cancer in men and women, with over 1 million diagnosed worldwide in 2018, although this is likely to be an underestimate.
In addition, increasing government funding for research activities and increasing number of clinical trials are also supplementing the growth of the global non-melanoma skin cancer treatment market. Furthermore, improving healthcare infrastructure is also supplementing the growth of the market. However, side-effects of radiation therapy may hamper the global non-melanoma skin cancer treatment market during the forecast period. In spite of that, increasing advancements in the field of innovative products can provide various opportunities for the further growth of the market.
North America is Expected to Dominate the Global Non-Melanoma Skin Cancer Market
The global non-melanoma skin cancer market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is expected to dominate the global non-melanoma skin cancer market within the forecast period attributed to the highly developed healthcare infrastructure and increasing cases of non-melanoma skin cancer in this region. For example; As per the American Academy of Dermatology; It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. Research estimates that non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year. In addition, increasing number of cancer treatment centers and presence of leading market players in this region are also supplementing the market growth.
Europe is projected to capture the second largest share of global non-melanoma skin cancer market owing to the increasing prevalence of occupational non-melanoma skin cancer in this region. In the European Union, more than 14.5 million workers are regularly exposed to solar UV radiation for more than 75% of their daily working hours. Occupational skin diseases, which also includes contact dermatitis, are estimated to lead to costs far beyond €5 billion annually in the EU alone.
Asia Pacific is anticipated to witness a significant growth in global non-melanoma skin cancer market owing to the increasing healthcare spending, improving healthcare infrastructure and increasing research and development for new and more effective treatments in this region.
Key Benefits for Global Non-Melanoma Skin Cancer Market Report–
- Global Non-Melanoma Skin Cancer Market report covers in-depth historical and forecast analysis.
- Global Non-Melanoma Skin Cancer Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
- Global Non-Melanoma Skin Cancer Market report helps to identify opportunities in marketplace.
- Global Non-Melanoma Skin Cancer Market report covers extensive analysis of emerging trends and competitive landscape.
Get Full information of This Report @ https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Non-Melanoma-Skin-Cancer-Market-Size/Summary
Global Non-Melanoma Skin Cancer Market Segmentation: –
By Drug Type:
- Radiation Therapy
- Electronic Brachytherapy
- External Beam Radiation Therapy
- Superficial Radiation Therapy
- Photodynamic Therapy
- Chemotherapy
By Application:
- Basal Cell Carcinoma
- T-Cell Lymphoma
- Squamous Cell Carcinoma
- Others
By End-User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
By Regional & Country Level:
- North America
- US.
- Canada
- Europe
- UK.
- France
- Germany
- Italy
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Latin America
- Brazil
- Mexico
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
About us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at alan@brandessenceresearch.biz
Website: https://brandessenceresearch.biz
Related Report:
Medical Devices Industry Reports 2019
